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Abstract 
The spectrum of serological markers associated with in-
flammatory bowel disease (IBD) is rapidly growing. Due 
to frequently delayed or missed diagnoses, the applica-
tion of non-invasive diagnostic tests for IBD, as well 
as differentiation between ulcerative colitis (UC) and 
Crohn’s disease (CD), would be useful in the pediatric 
population. In addition, the combination of pancreatic 
autoantibodies and antibodies against Saccharomyces 
cerevisiae  antibodies/perinuclear cytoplasmic antibody 
(pANCA) improved the sensitivity of serological markers 
in pediatric patients with CD and UC. Some studies sug-
gested that age-associated differences in the patterns 
of antibodies may be present, particularly in the young-
est children. In CD, most patients develop stricturing 
or perforating complications, and a significant number 
of patients undergo surgery during the disease course. 
Based on recent knowledge, serum antibodies are 
qualitatively and quantitatively associated with com-
plicated CD behavior and CD-related surgery. Pediatric 
UC is characterized by extensive colitis and a high rate 
of colectomy. In patients with UC, high levels of anti-
CBir1 and pANCA are associated with the development 
of pouchitis after ileal pouch-anal anastomosis. Thus, 
serologic markers for IBD can be applied to stratify 
IBD patients into more homogeneous subgroups with 
respect to disease progression. In conclusion, identifi-
cation of patients at an increased risk of rapid disease 
progression is of great interest, as the application of 
early and more aggressive pharmaceutical intervention 
could have the potential to alter the natural history of 
IBD, and reduce complications and hospitalizations.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Application of non-invasive diagnostic tests 
for the diagnosis of inflammatory bowel disease (IBD) 
and differentiation between ulcerative colitis (UC) and 
Crohn’s disease (CD) would be useful in the pediatric 
population. The combination of pancreatic autoantibod-
ies and antibodies against Saccharomyces cerevisiae  
antibodies/perinuclear cytoplasmic antibody improved 
the sensitivity of serological markers in pediatric pa-
tients with CD and UC. In addition, serologic markers 
for IBD can be applied to stratify IBD patients into 
more homogeneous subgroups with respect to disease 
progression. With this knowledge, clinicians will be able 
to stratify patients accordingly with regards to the risk 
of disease progression, create a personalized treatment 
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INTRODUCTION
Inflammatory bowel diseases (IBD), Crohn’s disease 
(CD), and ulcerative colitis (UC) are chronic relapsing 
and remitting disorders of  the digestive tract with un-
known etiology[1]. Previous studies suggested that IBD 
results from an aberrant innate and acquired immune re-
sponse to commensal microorganisms in genetically sus-
ceptible individuals[2,3]. This hypothesis is supported by 
the presence of  antibodies directed to microbial antigens 
and by the identification of  genetic polymorphisms, such 
as NOD2/CARD15 and toll-like receptor 4 variants in 
CD[4]. Besides genetic predisposition and environmental 
factors, innate immunity is assumed to be another major 
contributor to pathogenesis in IBD.
Incidence of  IBD is increasing, especially in pediatric 
patients with CD[5]. It is estimated that 15%-25% of  IBD 
patients present in childhood. Recent studies showed that 
up to 20% of  pediatric patients and 5%-15% of  adult 
patients with colon only involvement had diagnostic diffi-
culties if  they had UC or colonic CD[6]. Serologic markers 
may help to establish diagnosis of  IBD and to differenti-
ate CD from UC, particularly when they are combined. It 
is especially important in the pediatric population, where 
invasive diagnostic testing is less desirable. In CD, most 
patients develop stricturing or perforating complications, 
and a significant number of  patients undergo surgery 
during the disease course. Pediatric UC is more often 
associated with pancolitis and colectomy. Besides their 
diagnostic significance, current knowledge suggests that 
serologic markers can be a valuable aid in stratifying pa-
tients according to disease phenotype and risk of  compli-
cations in IBD.
Several circulating autoantibodies have been described 
in IBD. The two most intensively studied conserva-
tive antibodies are atypical perinuclear anti-neutrophil 
cytoplasmic antibodies (atypical pANCA), which are 
primarily associated with UC and anti-Saccharomyces cere-
visiae antibodies (ASCA), which are primarily associated 
with CD[4,7]. In pediatric IBD, sensitivity/specificity of  
pANCA in UC ranged between 57% to 83% and 65% to 
97%, respectively, whereas in CD, ASCA showed a sen-
sitivity/specificity in the range of  44% to 76% and 88% 
to 95%, respectively[8,9]. ASCA positivity or high titers are 
associated with complicated CD behavior (penetrating or 
stenosing disease) and could be useful markers for pre-
dicting the need for surgery in adults and children[10-12]. 
In pediatric studies, ASCA positivity increased with age 
at diagnosis[13] and was predictive for a more relapsing 
disease course [OR 2.9 (95%CI: 1.33-6.33)] in CD[14]. In 
addition, Trauernicht and Steiner[15] reported that serum 
ASCA antibodies are associated with lower anthropo-
metric data (lower mean weight and height Z-scores) at 
the diagnosis of  pediatric CD. pANCA is noted for its 
association with the ‘‘UC-like’’ phenotype in patients 
with CD[16,17]. Testing for ASCA and pANCA alone may 
have limited usefulness; therefore additional seromark-
ers are needed to improve the diagnosis, differentiation, 




Antibodies to Escherichia coli  outer membrane po-
rin C, Pseudomonas -associated sequence I2, and 
bacterial flagellin CBir: Several antibodies against mi-
crobial components have been detected in serum samples 
of  patients with IBD, including ones against outer mem-
brane porin C (anti-OmpC) of  Escherichia coli, against 
Pseudomonas-associated sequence I2 (anti-I2), and against 
bacterial flagellin CBir (anti-CBir1). Adherent-invasive E. 
coli has been found in ileal CD lesions, and OmpC has 
been shown to be required for these organisms to adhere 
to intestinal epithelial cells[18,19]. I2 was identified as a bac-
terial sequence from lamina propria mononuclear cells of  
active CD patients, and was shown to be associated with 
Pseudomonas fluorescens[20]. CBir1 is a flagellin related anti-
gen that was initially identified in the gut flora of  mice, 
and has the ability to induce colitis in immunodeficient 
mice[21].
Approximately 50% of  adult patients with CD were 
positive for these markers, which were insignificant in 
adult patients with UC and healthy subjects[22,23]. The 
prevalence of  anti-OmpC and anti-I2 was found to be 
11% and 56% in pediatric CD, respectively[10,13,24-28]. The 
occurrence of  antibodies varies in children of  different 
ages: children younger than 8 years old at diagnosis are 
predominantly anti-CBir1 positive and ASCA and anti-
OmpC negative, while those older than 8 are more com-
monly both ASCA and anti-CBir1 positive[13]. In children 
with CD, these strong serological responses to bacterial 
flagellin CBir antigens suggest that this antigen may have 
a potential role in the immunopathology of  the disease.
Anti-glycan antibodies: The most recently described 
serum markers directed against microbial antigens are 
anti-glycan antibodies. Glycans are predominant cell 
surface oligosaccharides found on microorganisms, im-
mune cells, erythrocytes, and tissue matrices. In IBD, 
the presence of  anti-glycan antibodies results from the 
interaction between the immune system and the glycosyl-
ated cell wall components of  such pathogens as fungi, 
yeast, and bacteria. Besides gASCA (which is very similar 
to conventional ASCA IgG), certain novel anti-glycan 
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antibodies were identified and associated with CD: anti-
mannobioside carbohydrate antibodies (AMCA), anti-
laminaribioside carbohydrate antibodies (ALCA), anti-
chitobioside carbohydrate antibodies (ACCA), anti-
laminarin carbohydrate antibodies (anti-L), and anti-chitin 
(anti-C) carbohydrate antibodies.
Anti-glycan markers are significantly increased in CD 
compared to UC and healthy controls[29,30]. However, 
only 16.9%-30.5% of  patients were positive for each of  
AMCA, ALCA, ACCA, anti-L, and anti-C markers in 
pediatric CD[31]. Since the presence of  anti-L and anti-C 
is low in ASCA-negative patients with CD, it has been 
proposed that these markers may bind different epitopes. 
Interestingly, the optimal cutoff  values for anti-glycan 
markers were different in children than in adult popula-
tions in a serological study by Rieder et al[31]; strikingly 
lower cutoff  points of  gASCA, ACCA, ALCA, AMCA, 
anti-L, and anti-C were observed in children compared to 
adult patients with CD.
Pancreatic autoantibodies: Autoantibodies against 
exocrine pancreas (PAB) were described for the first time 
in 1984[32], but the autoantigenic targets of  PAB were 
identified only in 2009[33,34]. The recognition of  glycopro-
tein 2 (GP2) as a major target antigen of  the droplet-like 
PAB (type I PAB) has been followed by the identification 
of  CUB/zona pellucida-like domain-containing protein 
1 (CUZD1) as another major antigenic target of  PAB 
giving the reticulogranular, cytoplasmic pattern by indi-
rect immunofluorescence (type II PAB). Both GP2 and 
CUZD1 are glycosylated membrane proteins residing in 
the acinar secretory storage granules of  the pancreas. It 
was previously believed that GP2 is exclusively expressed 
by pancreatic acinar cells, but recent studies have shown 
that GP2 is also present as a specific membrane-anchored 
receptor on the microfold (M) intestinal cells of  intestinal 
Peyer’s patches, and is essential for host-microbial inter-
action and the initiation of  bacteria-specific mucosal im-
mune responses[35,36]. Notably, GP2 overexpresses at the 
site of  CD inflammation in contrast to UC[33,37]. Respec-
tive data regarding CUZD1 expression in the intestine 
are sparse, with further research being needed to evaluate 
the relevance of  these autoantibodies in CD. Combined 
determination of  GP2 and CUZD1-specific autoantibod-
ies by indirect immunofluorescence using recombinantly 
expressed human embryonic-kidney cell autoantigens 
represents a new method in the serological diagnosis of  
IBD. Discrimination between positive and negative reac-
tions is considered to be easier in transfected cells than in 
primate tissues. The selective detection of  anti-GP2 and 
CUZD1 autoantibodies by enzyme-linked immunosor-
bent assay (ELISA) has also been recently developed[34].
PAB have been reported to be pathognomonic mark-
ers of  CD. A prevalence of  27% to 39% of  PAB was 
present in patients with CD, compared with only 0% 
to 5% in patients with UC[38-40]. Increased prevalence 
of  PAB has been found in unaffected first-degree rela-
tives[41]. Stöcker et al[38] reported that PAB could only be 
determined in the serum of  patients with CD. However, 
other studies found much higher (22%-24%) prevalence 
of  PAB in UC[42-44]. Although anti-GP2 only represents a 
small proportion of  PAB seropositive cases, anti-GP2 au-
toantibodies are detected in about 30% of  patients with 
CD and in 5%-12% of  patients with UC[45-47].
Ulcerative colitis
Autoantibodies against intestinal goblet cells: Se-
rological markers have been far less extensively studied 
in UC than in CD. Autoantibodies against different co-
lonic antigens have been found in patients with UC [e.g., 
goblet cell autoantibodies (GAB)]. In previous studies, 
GAB has been detected in adult patients with UC, with 
a prevalence of  28% to 30%. In contrast, other studies 
suggested a much lower prevalence in both diseases[42-44]. 
These conflicting results are likely due to methodological 
differences, such as enzyme-linked immunosorbent assay 
antigen substrates and the evaluation of  fluorescence pat-
terns. GAB produce mucin that has multiple functions: 
it serves as a lubricant, provides nonspecific protection 
against unwanted microbial agents, and hosts the normal 
bacterial flora. Through complicated and strictly regulated 
glycosylation, mucins act as a decoy in binding a range of  
different microbes and maintaining the normal intestinal 
flora. The significance of  these antibodies, however, has 
not been established and thus remains unclear.
DIAGNOSTIC VALUE OF NEW 
SEROLOGIC MARKERS IN IBD
In diagnostic workup of  IBD, a serologic test with high 
sensitivity and specificity is desired. The diagnostic value 
of  the new serologic markers for IBD is limited due to 
their low sensitivity and presence in other conditions, 
such as celiac disease, autoimmune diseases, and liver cir-
rhosis[48-50]. Sensitivity can be increased by the combina-
tion of  different antibodies. A role for serological testing 
in screening for IBD was suggested by several studies, 
but the low sensitivity of  these assays only provide a 
modest contribution to the identification of  IBD[8,24,51-53]. 
The diagnostic value of  the new serologic markers in 
children with IBD is shown in Table 1. A retrospective 
study of  300 pediatric patients tested in the IBD7 panel 
(anti-OmpC, anti-CBir-1, ASCA, and ANCA, Serology 7, 
Prometheus, Sandiego, CA, United States) for the evalu-
ation of  pediatric IBD resulted in a 67% sensitivity and 
76% specificity. Consequently, this panel has a limited 
clinical utility in screening for pediatric IBD[53].
In pediatric CD, each anti-OmpC, anti-I2, or anti-
CBir1 antibody was detected in 11%-55% of  patients as a 
single marker. In a prospective pediatric study using com-
bined analysis (anti-OmpC, anti-I2, anti-CBir1 or ASCA), 
77% of  patients with CD were positive for at least one 
microbial-driven antibody[26]. Therefore this method pro-
vided modest support for the diagnosis of  CD. 
Single glycan markers have limited clinical value for 
the primary diagnostic workup for CD due to their low 
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increased sensitivity; therefore, it may be recommended 
in the diagnostic procedure of  IBD[42,44]. Diagnostic ac-
curacy of  the combined novel antibodies with conven-
tional serological markers in children with IBD is shown 
in Table 2[44].
In a recent study, Bogdanos et al[45] observed a signifi-
cantly higher prevalence of  PAB compared to anti-GP2 
in UC (20.6% vs 8.8%, P < 0.003), whereas the difference 
between PAB and anti-GP2 did not reach a statistically 
significance level in CD (38.5% vs 30.2%, P = 0.108), re-
spectively. Thus, anti-GP2 testing by ELISA assay seems 
to be more specific for CD than for PAB testing, so it 
may improve the differentiation between CD and UC.
In UC, the most frequently studied serological marker 
is pANCA. Besides pANCA, in our study the prevalence 
of  GAB was significantly increased in patients with UC 
in comparison to CD and controls (UC, 12.2%; CD, 1.9%; 
controls, 1.9%; P = 0.02). Sensitivity can be significantly 
increased with combinations of  different antibodies. For 
example, pANCA and/or GAB together had a sensitivity 
of  approximately 80% for UC[44].
ASSOCIATION WITH IBD PHENOTYPES 
AND PROGNOSIS
In patients with CD at diagnosis, most patients have 
inflammatory type disease[56,57]. Nevertheless, during the 
disease course the development of  complicated behavior 
in the pediatric population is a common feature[58]. In the 
largest pediatric cohort with CD (n = 989), the cumula-
tive incidence of  stricturing or penetrating complications 
was found to be 13%, 27%, and 38%, 1, 5, and 10 years 
after the diagnosis of  IBD, respectively[58]. Furthermore, 
small bowel disease is more frequently correlated with 
the development of  complicated disease behavior than 
in isolated colonic disease. Based on these observations, 
sensitivity. From the entire panel, gASCA came out as the 
most accurate for the diagnosis of  pediatric CD (sensitiv-
ity: 62.7%, specificity: 95.6% CD vs controls, and 88.9% 
CD vs UC)[31]. With respect to the latest two novel mark-
ers, the addition of  Anti-L and Anti-C to gASCA and 
pANCA further improved discrimination between CD 
and UC (P < 0.001) in a large pediatric and adult cohort 
with IBD (n = 818, 517 CD, 301 UC)[30]. More specifical-
ly, nearly three-quarters of  the patients with CD showed 
seropositivity for at least one of  the aforementioned sev-
en anti-glycan antibodies[30,31]. Anti-glycan antibodies may 
be particularly important in ASCA-negative patients with 
CD. Rieder et al[31] found that 40.9% of  ASCA-negative 
pediatric patients with CD were positive for at least one 
other anti-glycan marker, suggesting that these novel anti-
bodies may further improve serological diagnosis for CD. 
Similarly, other studies found that about half  of  ASCA 
negative adult patients were positive for ALCA, ACCA, 
or AMCA[29,54]. In concordance with the results published 
by Rieder et al[55], Seow et al[30] demonstrated that all the 
anti-glycan antibodies were highly specific for IBD, par-
ticularly for CD (85.4%-97.7%), and were more prevalent 
in CD vs UC (P < 0.0015). In this large pediatric and 
adult cohort with IBD, anti-C showed the highest speci-
ficity of  97.7, followed by ACCA at 97%, then anti-L at 
96.7%. Due to the combined use of  these markers, the 
specificity for CD increases up to 100%[29,55].
While the specificity of  PAB for CD is high, its 
sensitivity is low. In our study the presence of  PAB was 
significantly higher in CD (34%) and UC (20.4%) com-
pared with the pediatric control cohort (0%, P < 0.0001). 
Specificity of  PAB was 100%; however, sensitivity was 
low. The combination of  PAB and antibodies against 
ASCA/pANCA improved the sensitivity of  serological 
markers in CD (87.4%) and in UC (79.6%); specificity 
was 89.3% and 93.2%, respectively[44]. Combinations of  
these antibodies, particularly with ASCA, have shown 
  Marker Sensitivity Specificity PPV NPV Ref.
CD UC CD vs  UC
  Anti-Omp    11%-34%      5%-25% 75%-95% 57.9%-69% 51.6%-53.3% [8,24,25]
  Anti-CBir    52%-56% ND ND ND ND [10,13,26]
  Anti-I2 44.4%-50% 41.7%-42%       58%-58.3%    51.6%-54.3% 51.1%-53.7% [27,28]
  gASCA    60.7%-62.7%    11.1%-14.6%    85.4%-88.9%    87.1%-92.5% 52.2%-55.9% [301,31]
  ACCA   8.7%-22%         3%-18.5% 81.5%-97%    72.2%-83.3% 32.4%-38.2% [301,31]
  ALCA    19.7%-30.5%      7.6%-14.8%    85.2%-92.4%    81.8%-81.6% 35.9%-40.1% [301,31]
  AMCA    12.2%-16.9%      7.6%-14.8%    85.2%-96.7%    71.4%-86.3%   31.9%-39.06% [301,31]
  Anti-L    18%-22%      3.3%-14.8%    85.2%-96.7%    76.5%-90.3%   33.3%-40.07% [301,31]
  Anti-C 10.2%-22%      2.3%-14.8%    85.2%-97.7%    76.5%-83.3% 33.3%-38.8% [301,31]
  PAB       34%-38.5%    20.4%-20.6%    79.4%-79.6%    62.5%-65.1% 54.7%-56.5% [44,451]
  Anti-GP2 30.2% 8.8% 91.2% 77.4% 56.7% [45]1
  GAB 12.2% 1.9%  98.1%2  86.5%2  52.7%2 [44]
Table 1  Diagnostic value of the new serologic markers in children with inflammatory bowel disease
1Mixed pediatric and adult cohort; 2Ulcerative colitis (UC) vs Crohn’s disease (CD). ND: No data available; Anti-OmpC: Antibodies against outer membrane 
porin C of Escherichia coli; Anti-CBir1: Antibodies against bacterial flagellin CBir1; Anti-I2: Antibodies against the Pseudomonas-associated sequence; ASCA: 
Antibodies against Saccharomyces cerevisiae; AMCA: Anti-mannobioside carbohydrate antibodies; ALCA: Anti-laminaribioside carbohydrate antibodies; 
ACCA: Anti-chitobioside carbohydrate antibodies; Anti-L: Anti-laminarin carbohydrate antibodies; Anti-C: Anti-chitin carbohydrate antibodies; PAB: 
Pancreatic antibodies; Anti-GP2: Antibodies against glycoprotein 2; GAB: Antibodies against intestinal goblet cells; IBD: Inflammatory bowel disease; PPV: 
Positive predictive value; NPV: Negative predictive value.
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a more aggressive treatment should be considered in this 
large subgroup of  pediatric patients with CD. Conse-
quently, the evaluation of  relevant phenotype-serotype 
correlations may provide important prognostic informa-
tion. Association of  the new serologic markers with phe-
notype in pediatric CD is summarized in Table 3.
Antibodies directed to bacterial antigens were re-
ported as being qualitatively (presence) and quantitatively 
(titer) associated with aggressive disease behavior in 
both children and adults[10,26,59,60]. The first prospective 
pediatric study conducted by Dubinsky and co-workers 
demonstrated that the degree of  the immune response 
to ASCA, anti-I2, anti-OmpC, and anti-CBir1 correlated 
with internal penetrating, stricturing disease, and the 
need for surgery in a large cohort with CD (n = 196). 
The risk of  developing penetrating and/or stricturing 
CD was increased 11-fold in those subjects with immune 
responses to all four antigens (anti-12, anti-OmpC, anti-
CBir1, and ASCA) compared to seronegative cases (OR 
= 11, 95%CI: 1.5-80.4, P = 0.03). Moreover, in this study, 
the highest antibody sum group and quartile sum score 
group showed the most rapid disease progression[26]. 
These initial findings were confirmed in another larger 
study of  796 pediatric CD patients using ASCA, anti-
OmpC, and anti-CBir1[10].
Recent studies demonstrated that seropositivity for 
anti-glycan antibodies was associated with early disease 
onset, small bowel disease, complicated disease behav-
ior, and CD-related surgery in both adult and pediatric 
CD[4,29,30,31,54,55,61,62]. This was also found in both qualitative 
(number of  positive antibodies) and quantitative (antibody 
titers) immune response. In a cross-sectional pediatric 
study, ALCA and anti-L had the strongest association 
with complications[31]. In this pediatric population, most 
of  the anti-glycan markers, except for ACCA and anti-C, 
were associated with complicated disease behavior and 
ALCA with CD-related surgery. Only gASCA was as-
sociated with terminal ileal disease location. Surprisingly, 
gASCA was inversely correlated with early disease onset 
in this pediatric cohort[31], but this link was found to be 
positive in adult CD[4,55,63]. This difference may arise from 
the distinct nature of  the intestinal immune system in 
children.
There are conflicting results related to the associa-
tion between PAB and CD phenotype in adult cohorts. 
Increased prevalence of  PAB was observed in patients 
with early onset of  disease, and stricturing or penetrating 
phenotypes[39,40,42,43,64]. Lakatos et al[42] reported an associa-
tion between PAB positivity, perianal disease, and EIMs. 
However, in our pediatric study, we found that the pres-
ence of  PAB was not associated with disease phenotype 
in CD[44]. It is difficult to compare the data of  these stud-
ies, since age may affect localization and behavior as well.
In some studies, the relation between anti-GP2 and 
CD phenotype was also evaluated. In mixed pediatric and 
adult cohort with CD (n = 169), humoral autoreactivity 
to GP2 and ASCA applying ELISA has been reported 
to be associated with ileocolonic location, suggesting a 
  Marker Sensitivity Specificity PPV NPV Ref.
  CD vs controls ASCA 35.5%-72.8% 95.2%-96.5% 91%-93.8% 59.9%-77.8% [44,451]
PAB 34.0%-43.8%  100%  100% 60.2% [44,451]
Anti-GP2 30.2%    96% 88.3% 57.9% [45]
pANCA 33.0% 94.2% 85.1% 58.4% [44]
GAB   1.9% 98.1% 50.0% 50.0% [44]
PAB and/or ASCA 79.6% 95.2% 94.3% 82.3% [44]
Anti-GP2 and/or ASCA 50.9% 92.9% 87.8% 65.4% [45]
PAB and/or ASCA and/or pANCA 87.4% 89.3% 89.1% 87.6% [44]
PAB and /or ASCA/ pANCA- 53.4% 95.2% 91.8% 67.1% [44]
ASCA+/pANCA- 51.5% 95.2% 91.5% 66.2% [44]
  UC vs controls pANCA 77.5% 94.2% 93.0% 80.9% [44]
GAB 12.2% 98.1% 86.5% 52.8% [44]
PAB 20.4%-23.5%  100%  100% 55.6% [44,451]
Anti-GP2   8.8%    96% 68.8% 51.3% [45]1
ASCA 6.9%-26.5% 95.2%-96.5% 66.3%-84.7% 50.9%-56.4% [44,451]
ASCA2 16.3% 95.2% 77.3% 53.2% [44]
PAB and/or pANCA 79.6% 94.2% 93.2% 82.2% [44]
PAB and/or pANCA and/or GAB 79.6% 94.2% 93.2% 82.2% [44]
Anti GP2 and/or ASCA 14.7% 92.9% 67.4% 52.1% [45]
GAB+/pANCA+ 12.2% 98.1% 86.5% 52.8% [44]
PAB+/pANCA+ 18.4%  100%  100% 55.1% [44]
rPAB+/pANCA+ 22.4%  100%  100% 56.3% [44]
GAB+/PAB+/pANCA+   4.1%  100%  100% 51.0% [44]
Table 2  Diagnostic accuracy of the combined novel antibodies with conventional serological markers in children with inflammatory 
bowel disease[44,45]
1Mixed pediatric and adult cohort; 2Diagnostic value of antibodies against Saccharomyces cerevisiae (ASCA) antibodies in ulcerative colitis (UC) patients 
without primary sclerosing cholangitis (PSC). PAB: Pancreatic antibodies; Anti-GP2: Antibodies against glycoprotein 2; pANCA: Perinuclear anti-
neutrophil cytoplasmic antibodies; GAB: Antibodies against intestinal goblet cells; IBD: Inflammatory bowel disease; CD: Crohn’s disease; PPV: Positive 
predictive value; NPV: Negative predictive value.
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role for GP2 as a receptor on M cells in intestinal Peyer’s 
patches[45]. Moreover, in this cohort, the presence of  anti-
GP-2 was associated with younger age at the onset of  
the disease (< 16 years), stricturing behavior, and perianal 
disease in CD[45]. Similarly, Pavlidis et al[46] demonstrated 
that patients with colonic CD do not show significant an-
tibody reactivity against GP2 compared to those who had 
ileal localization; the site of  GP2-rich M cells. However, 
a Belgian study by Op De Beéck et al[65] did not find any 
association between anti-GP2 seropositivity and clinical 
phenotype in CD (n = 164) using the same ELISA.
In patients with UC, both anti-CBir1 and pANCA 
positivity correlated with the development of  pouchitis 
after ileal pouch-anal anastomosis. In a study by Fleshner 
et al[66], diverse patterns of  reactivity to microbial antigens 
were manifested as different forms of  pouchitis (n = 
238, age range: 8-81 years). Anti-CBir1 positivity indi-
cated acute pouchitis only in patients who have low-level 
pANCA expression, with increased incidence of  chronic 
pouchitis only in patients who had high-level pANCA 
expression. In a meta-analysis by Singh et al[67], the risk 
of  chronic pouchitis after IPAA was higher in ANCA-
positive patients, but the risk of  acute pouchitis was 
unaffected by ANCA status. These data had a significant 
influence on the patients’ treatment in post-operative 
course. The studies could not demonstrate any associa-
tion between the presence of  GAB and clinical presenta-
tion, medical therapy, or need for surgery in patients with 
UC. 
ASSOCIATION WITH THE RESPONSE TO 
THERAPY AND DISEASE ACTIVITY
Recent studies have highlighted the connection of  sero-
logic markers with biologic therapies. Previous studies 
demonstrated that ASCA signals do not predict response 
to anti-tumor necrosis factor (TNF)-α therapies in CD[4,68]. 
Comparative findings were reported regarding the effect 
of  biological agents in the behavior of  anti-GP2 antibod-
ies. Belgian investigators did not find a robust effect of  
infliximab and adalimumab in patients followed up for 6-44 
mo[65].
No association was detected between anti-glycan 
markers and the response to corticosteroids and disease 
activity in children with CD[31]. Similarly, in our study, we 
could not find any association between serum antibodies 
of  PAB, ASCA, and ANCA and response to therapy[44].
Dubinsky et al[69] reported that a combination of  
phenotype, serotype, and genotype is the best predictive 
model of  non-response to anti-TNFα agents in pediatric 
patients. In this study, anti-OmpC, anti-CBir1, anti-I2, 
ASCA, and pANCA serum markers were analyzed. The 
most predictive model included the presence of  three 
novel “pharmacogenetic” loci, the previously identified 
BRWD1, pANCA, and UC diagnosis (P < 0.05). The 
relative risk of  non-response increased 15-fold when the 
number of  risk factors increased from 0-2 to ≥ 3 (P < 
0.0001)[69].
Based on longitudinal analysis, the presence of  an-
tibodies in IBD is relatively constant during the disease 
course[62,70]. However, the prevalence of  ASCA, anti-
OmpC, and anti-I2 has been found to be more frequent 
when the disease persists for a long time[12,60]. Further-
more, disease activity, CRP levels, or response to corti-
costeroids does not appear to influence marker levels in 
longitudinal studies. Therefore, serial measurement of  
antibodies may not provide additional information for 
the evaluation of  IBD[31,70].
CONCLUSION
The correct diagnosis and classification of  IBD as ei-
ther CD or UC is essential for choosing the appropriate 
therapy. Combined application of  the novel antibodies 
(PAB/GP2) with conventional serology markers (ASCA/
pANCA) increased sensitivity. Therefore, the use of  
combinations may be advisable in the diagnostic work-up 
of  selected cases. Moreover, childhood-onset CD often 
leads to complicated disease (stricturing or penetrating) 
with increasing prevalence in parallel to disease duration. 








  gASCA Early disease onset [301,31]
Ileal disease location
Complicated disease behavior 
Perianal disease
CD-related surgery
  ACCA Complicated disease behavior CD-
related surgery
[30]1
  ALCA Ileal disease location [301,31]
Complicated disease behavior CD-
related surgery
  AMCA Complicated disease behavior 
perianal disease
[301,31]
  Anti-L Ileal disease location [301,31]
Complicated disease behavior 
Perianal disease
CD-related surgery








Table 3  Association of the new serologic markers with 
phenotype in pediatric Crohn’s disease
1Mixed pediatric and adult cohort. Anti-OmpC: Antibodies against outer 
membrane porin C of Escherichia coli; Anti-CBir1: Antibodies against 
bacterial flagellin CBir1; Anti-I2: Antibodies against the Pseudomonas-
associated sequence; ASCA: Antibodies against Saccharomyces cerevisiae; 
AMCA: Anti-mannobioside carbohydrate antibodies; ALCA: Anti-
laminaribioside carbohydrate antibodies; ACCA: Anti-chitobioside 
carbohydrate antibodies; Anti-L: Anti-laminarin carbohydrate antibodies; 
Anti-C: Anti-chitin carbohydrate antibodies; Anti-GP2: Antibodies against 
glycoprotein 2. 
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In CD, information gained from a serologic profile, both 
qualitatively and quantitatively, may help to determine 
the likelihood of  a more severe phenotype. In addition, 
pediatric UC is associated with pancolitis and a higher 
risk of  colectomy. In patients with UC, serologic markers 
are associated with the development of  pouchitis after 
ileal pouch-anal anastomosis. With this knowledge, clini-
cians will be able to stratify patients regarding the risk 
of  disease progression, create a personalized treatment 
strategy, and try to modify disease course, thus improv-
ing long-term prognosis. Further simultaneous prospec-
tive multicentric studies are needed to evaluate the exact 
prognostic role of  serologic markers which may help in 
the individual therapeutic management of  pediatric and 
adult IBD.
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